Table 1.

Clinical and cytogenetic/molecular risk factors for post-MPN AML

Risk factors
Clinical
Age >60-65 y
Red blood cell transfusion dependency
Prior treatment exposure (pipobroman, 32P, chlorambucil, busulfan)
Prior thrombosis*
Myelofibrosis or prefibrotic ET/PV
Laboratory
Leukocytosis (>15 × 109/L to 30 × 109/L)
Anemia (Hgb <10 g/dL)
Thrombocytopenia (<50 × 109/L to 100 × 109/L)
Peripheral blast count (>1% to 10%)
Extreme thrombocytosis (>1000 × 109/L)*
Elevated serum IL-8†
Elevated serum C-reactive peptide†
Cytogenetics
Monosomal karyotype‡
Complex karyotype or sole or 2 abnormalities that include +8, −7/7q, i(17q), −5/5q−, 12p−, inv(3), 11q23 rearrangement§
Chromosome 17p deletion
Molecular
TP53, TET2, ASXL1, EZH2, SRSF2, IDH1/2, RUNX1, U2AF1Q157

Hgb, hemoglobin.

^*Risk factors found specific to the ET subtype.

^†Risk factors found specific to the MF subtype.

^‡Defined as 2+ autosomal monosomies or single autosomal monosomy associated with at least 1 structural abnormality.

^§As per current DIPSS-Plus criteria.²⁴